Pfizer vs Sanofi (PFE vs SAN.PA)
Sanofi trades at 24.3x earnings vs 40.1x for Pfizer; Sanofi grows sales faster (+15.7% vs -0.4%). Margins, debt and dividend, Nov 2026.
Quick answer
On today's data (November 19, 2026): Sanofi looks cheaper on P/E: 24.3x against 40.1x for Pfizer. Sanofi grows faster: sales +15.7% against -0.4% for Pfizer in the latest quarter. Sanofi has the better net margin: 8.2% against 6.3% for Pfizer.
This is a snapshot of the numbers, not a recommendation to buy or sell.
Your first analysis is free with a free account, no card.
Short answer
On P/E as of November 19, 2026, Pfizer is the more expensive of the two: it trades at 40.1x its annual earnings against 24.3x for Sanofi. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. What helps read that gap: Pfizer sales -0.4% against +15.7% for Sanofi in the latest quarter; net margin 6.3% against 8.2%; net debt for Pfizer: 2.0x EBITDA against 0.9x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.
Pfizer (PFE) and Sanofi (SAN.PA) compete in healthcare and pharma. Here are Pfizer and Sanofi side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Pfizer or Sanofi.
Pfizer vs Sanofi: the figures
| Figure | Pfizer | Sanofi |
|---|---|---|
| Share price | $28.06 (November 18, 2026) | €84.08 (November 19, 2026) |
| Market cap | $159.9 billion | €100.9 billion |
| P/E (TTM) | 40.1x | 24.3x |
| Forward P/E | 9.5x | 8.8x |
| Revenue growth (quarter) | -0.4% | +15.7% |
| Net margin (TTM) | 6.3% | 8.2% |
| Net debt / EBITDA | 2.0x | 0.9x |
| Dividend yield | 6.13% | 4.76% |
| Beta | 0.30 | 0.26 |
Pfizer and Sanofi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Pfizer or Sanofi figure is not available, and we never estimate it.
3 key differences between Pfizer and Sanofi
- Valuation: Pfizer trades at 40.1x its annual earnings and Sanofi at 24.3x; the market pays more for each dollar of Pfizer profit, usually because it expects more growth.
- Growth: Sanofi grew sales +15.7% year on year in its latest quarter, against -0.4% for Pfizer.
- Dividend: Pfizer yields 6.13% at today's price and Sanofi yields 4.76%.
Pfizer or Sanofi: which fits your profile
- If you want growth: Sanofi is growing faster today, with sales +15.7% against -0.4% for Pfizer and also trades on a lower P/E (24.3x against 40.1x). Investors who prioritise growth usually accept more volatility; the P/E only shows what you pay today for each unit of the last 12 months' earnings.
- If you want income (dividends): Pfizer pays the higher dividend relative to its price.
- If you prefer caution: Sanofi has less debt relative to its profit, which usually gives more room in a bad year.
- If price is what matters most to you: Sanofi trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Pfizer nor Sanofi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
Verdict: Pfizer or Sanofi?
Of the 6 comparable figures in the table, Pfizer stands out on 1 (dividend yield) and Sanofi stands out on 5 (sales growth, net margin, lower P/E, less debt over EBITDA and lower volatility (beta)). That does not name a winner between Pfizer and Sanofi: the table is a snapshot of today, not a forecast.
Keep reading free.
Create your free account to continue reading “Pfizer vs Sanofi (PFE vs SAN.PA)”.
No card required
Pfizer vs Sanofi by dimension
Strategy
Pfizer operates in healthcare and pharma and Sanofi in healthcare and pharma, so they only fight for the same customer when the sector overlaps.
Products and AI
Pfizer and Sanofi sell different things: Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. And for Sanofi: Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines.
Margins
Sanofi is more profitable: it keeps 8.2 of every 100 it sells, against 6.3 for Pfizer.
Valuation
Pfizer trades at the higher P/E (40.1x against 24.3x for Sanofi). A higher P/E is only justified if earnings grow faster.
Risks
Pfizer is the more volatile: beta 0.30 against 0.26 for Sanofi.
Competitors
Other companies investors compare Pfizer and Sanofi with: Thermo Fisher, UnitedHealth, Bayer, argenx. Thermo Fisher · UnitedHealth · Bayer · argenx
How Pfizer and Sanofi make money
Pfizer (PFE)
Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. The U.S. is its biggest market. Full Pfizer analysis.
Sanofi (SAN.PA)
Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. It sells to hospitals, pharmacies and health systems, with the US and Europe as its main markets. Full Sanofi analysis.
Frequently asked questions: Pfizer vs Sanofi
What is the difference between Pfizer and Sanofi?
Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. Both are in healthcare and pharma. As of November 19, 2026: P/E 40.1 vs 24.3; net margin 6% vs 8% (Pfizer vs Sanofi).
Is Pfizer or Sanofi the better stock?
Choosing between Pfizer and Sanofi depends on what you are looking for. Sanofi is growing faster right now, and Sanofi trades on the lower P/E. Fintols does not tell you whether to buy Pfizer or Sanofi: it shows you the differences so you can decide.
Which pays a higher dividend, Pfizer or Sanofi?
As of November 19, 2026, Pfizer yields 6.13% and Sanofi yields 4.76%. Also check how much of their profit Pfizer and Sanofi pay out: if it is more than they earn, it cannot last.
Which is more expensive, Pfizer or Sanofi?
On P/E, Pfizer (40.1x) is more expensive than Sanofi (24.3x) as of November 19, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Which is more profitable, Pfizer or Sanofi?
On net margin, Sanofi (8.2%) keeps more of every 100 it sells than Pfizer (6.3%), as of November 19, 2026.
Which has more debt, Pfizer or Sanofi?
As of November 19, 2026, Pfizer owes 2.0x its EBITDA and Sanofi owes 0.9x its EBITDA (net debt over EBITDA).
Can I own both Pfizer and Sanofi?
Yes. Many people spread their money across several companies, such as Pfizer and Sanofi, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Pfizer or Sanofi.
To go deeper: Does Pfizer pay a dividend? and Does Sanofi pay a dividend?.
Related comparisons for Pfizer and Sanofi
More companies like Pfizer and Sanofi: healthcare and pharma stocks. Educational content about Pfizer and Sanofi, not investment advice.
Full analyses: Pfizer and Sanofi. Machine-readable summary: llms.txt.
Your first analysis is free with a free account, no card.
Your own analysis of Pfizer or Sanofi.
Create a free account and run your first full analysis in a minute. No card needed.
- How it makes money
- Valuation scenarios
- What could go wrong
First full analysis free · No card